Liver Cancer Treatment in Korea: What's the Typical Process? (2026 Update)

Liver cancer treatment in Korea is planned not only by tumor size and number but also by liver function grade (Child-Pugh), with the pathway chosen among resection, local therapy, embolization, systemic drug therapy, and transplantation. Korea's national 5-year relative survival rate for liver cancer in 2019–2023 was 40.4% — this is a nationwide statistic, not tied to any specific hospital.

Key Summary

• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registry Statistics, 2019–2023), while the U.S. SEER figure for liver and intrahepatic bile duct cancer is 21.9% (SEER 2016–2022) — both are national-level statistics, not hospital-specific figures.
• Liver cancer treatment decisions depend not only on tumor status but also on liver function (Child-Pugh grade) and portal pressure, using staging systems such as BCLC.
• In many cases, diagnosis can be made using imaging (contrast-enhanced CT/MRI) and tumor markers like AFP alone, without requiring a biopsy.
• The core treatment differs by stage: resection, radiofrequency ablation, or liver transplantation (very early to early stage), transarterial chemoembolization (intermediate stage), and systemic drug therapy (advanced stage).
• The remote review (pre-arrival review) fee is KRW 1,000,000 (about US$730), which is deducted from treatment costs if a treatment contract is signed.

How Are Diagnosis and Staging Determined?

• In patients with liver cirrhosis or chronic hepatitis, liver cancer is often diagnosed without a biopsy when contrast-enhanced CT or MRI shows a characteristic blood flow pattern (strong enhancement in the arterial phase followed by washout). Tumor markers such as AFP are evaluated alongside this.
• Staging takes three factors into account together: first, the number, size, and vascular invasion of tumors; second, liver function grade (Child-Pugh), which combines bilirubin, albumin, coagulation levels, ascites, and jaundice; and third, the patient's overall physical condition. Based on these three factors, staging systems such as BCLC classify disease into very early/early stage, intermediate stage, advanced stage, and terminal stage.
• A biopsy is only added when imaging findings are ambiguous or when metastasis from another cancer is suspected.

What Treatment Is Given at Each Stage?

• Stage 1: Very early/early stage — If the tumor is small, few in number, and liver function is good, liver resection (laparoscopic or robotic options available) is the first choice; if resection is not feasible, radiofrequency ablation is used to burn away the tumor. If liver function has significantly declined but tumor size and number fall within established criteria, liver transplantation becomes the definitive treatment.
• Stage 2: Intermediate stage — When multiple tumors exist within the liver, transarterial chemoembolization (TACE), which blocks blood vessels feeding the tumor, is the primary approach; this may be combined with radioembolization, stereotactic radiotherapy, or particle therapy, or systemic drug therapy may be prioritized.
• Stage 3: Advanced stage — When there is vascular invasion or spread outside the liver, systemic drug therapy becomes central. A combination of immune checkpoint inhibitors and anti-angiogenic agents is now part of first-line standard treatment, and oral targeted therapies are used depending on conditions.
• Stage 4: Severely impaired liver function — Since chemotherapy can further damage the liver, the focus shifts to symptom control, preserving liver function, and evaluating transplant eligibility.
• Proton and heavy-ion (particle) therapy are considered when resection is not feasible and the tumor is near major blood vessels or bile ducts, making surgery or ablation risky; liver cancer is among the cancers with relatively broad indications for particle therapy.

What Side Effects and Recovery Should Be Expected After Treatment?

• After radiofrequency ablation and embolization, fever, abdominal pain, nausea, and fatigue commonly occur for a day or two, usually subsiding within several days, allowing patients to return home within about 10 days.
• After liver resection, wound pain occurs alongside a recovery period during which the remaining liver regains function, so liver values are monitored continuously through blood tests.
• Immunotherapy can cause delayed inflammatory reactions in the thyroid, liver, intestines, and skin, requiring scheduled testing even after returning home; liver transplantation requires the longest recovery time and adjustment of immunosuppressant medications.
• Typical target stay durations are about 10 days for radiofrequency ablation/embolization, 2–3 weeks for liver resection, 3–5 weeks for particle therapy, and 6–8 weeks or more for liver transplantation, with outpatient follow-up continuing afterward.

How Are Follow-Up and Post-Return Care Managed?

• Since liver cancer can recur in other areas of the liver beyond the treated site, follow-up intervals tend to be frequent. For the first 1–2 years after treatment, contrast-enhanced CT/MRI and AFP testing are repeated every few months, with intervals extended afterward.
• Patients with chronic hepatitis B or C must continue antiviral therapy and liver function tests for life. A handover document noting the next test schedule and current medications is provided so that local medical staff can continue care.

FAQ — Can a Treatment Plan Be Made Without a Biopsy?

Yes. Liver cancer is often diagnosed based on imaging findings, tumor markers (such as AFP and PIVKA-II), and hepatitis status, allowing review without a biopsy. However, if imaging findings are ambiguous, a biopsy may be additionally required, and the reason for this will be specified in the written opinion.

FAQ — Can Foreign Patients Receive a Liver Transplant?

A living donor within the family is required, and the case undergoes review in accordance with Korean law. Since deceased-donor organs are prioritized for domestic waitlisted patients, transplants for foreign patients are considered on the premise of living-donor transplantation. The tumor size and number must fall within established criteria, with no metastasis outside the liver; eligibility and required documentation are explained during the remote review stage.

Sources and Notes

• This article was written based on National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea, Central Cancer Registry), SEER 2016–2022, National Cancer Center Korea, and liver cancer-related content from NCCN patient guidelines.
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment should always be determined through consultation with medical professionals.